<DOC>
	<DOCNO>NCT02651012</DOCNO>
	<brief_summary>A Study Evaluate Efficacy Safety Sarecycline Treatment Acne Vulgaris .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety 1.5 mg/kg/Day Sarecycline v Placebo Treatment Acne Vulgaris</brief_title>
	<detailed_description>Treatment inflammatory lesion moderate severe acne vulgaris subject 9 45 year age oral sarecycline 1.5 mg/kg/day compare placebo subject moderate severe facial acne vulgaris base Investigator 's Global Assessment ( IGA ) score inflammatory lesion count . Safety monitor evaluate throughout 12-week study .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>A subject consider inclusion study he/she meet follow criterion : Is male female , 9 45 year age , inclusive Has body weight 72 lb 300 lb , inclusive Has facial acne vulgaris : 20 50 inflammatory lesion ( papule , pustule , nodule ) 100 noninflammatory lesion ( open close comedo ) No two nodule IGA score moderate ( 3 ) severe ( 4 ) Has negative urine pregnancy test baseline female childbearing potential Agrees use effective method contraception throughout study , applicable Refrain use acne medication medicate cleanser , avoid excessive sun exposure tan booth duration study Is able swallow tablet A subject excluded participation he/she meet follow criterion : Has dermatological condition face ( e.g. , skin burn , sunburn , beard , mustache ) could interfere clinical evaluation Has history follow : Allergy tetracyclineclass antibiotic ingredient study drug Pseudomembranous colitis antibioticassociated colitis Treated type cancer within last 6 month Has know resistance tetracycline Has receive follow treatment within 12 week randomization : Systemic retinoids Systemic corticosteroid Androgens/antiandrogenic therapy ( e.g. , anabolic steroid , spironolactone ) Nonmedicated procedure treatment acne Has use acne affect treatment without appropriate washout period Has initiate hormonal contraceptive use within 12 week prior randomization plan initiate switch hormonal contraceptive product study period Is pregnant , lactating , plan pregnancy study period Has disorder cause hyperandrogenism include , limited , polycystic ovary syndrome , adrenal ovarian tumor , Cushing 's disease , congenital adrenal hyperplasia Has druginduced acne Has significant intercurrent illness , psychiatric disposition , factor , opinion Investigator Medical Monitor , preclude participation study Is currently participate , participate within 30 day prior randomization period , investigational drug device study Has previously participate clinical trial involve use sarecycline Is judge Investigator unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>acne</keyword>
	<keyword>acne vulgaris</keyword>
	<keyword>papule</keyword>
	<keyword>pustule</keyword>
	<keyword>adolescent acne</keyword>
</DOC>